Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is a biopharmaceutical company specializing in the development of drugs for metabolic and endocrine disorders. The termination of the master license agreement with Ligand Pharmaceuticals may present some short-term challenges, but the company's strong clinical program pipeline and focus on differentiated assets like VK2809 and VK2735 indicate long-term potential. With upcoming milestones including enrollment completion in VANQUISH-2 and Phase 3 initiation and data readouts, Viking is poised for growth and may become a valuable asset for potential partnerships or strategic alternatives.

Bears say

Viking Therapeutics is currently facing multiple risks in the development of their pipeline, including a lack of credit for their VK2809 and VK0214 programs compared to the focus on their VK2735 program and the risk of not replicating weight loss and tolerability in Phase 3 studies. Additionally, there is a commercial risk of not being able to secure manufacturing agreements for VK2735 or the cost of its API being too high. However, the company does have a strong cash runway that will support development and strategic flexibility for their pipeline, potentially mitigating some of these risks.

Viking Therapeutics (VKTX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 9 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $95.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $95.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.